The starting point coincided with the approval date of the first GLP-1 RA, exenatide (BYETTA), April 28, 2005
[5] One honest caveat, though: theres no direct head-to-head Phase 3 trial yet, so all of this is stitched together from separate trials
When administered together, the GH response is synergistic typically 2-5 times greater than either peptide alone because GHRH primes the somatotroph's secretory capacity while GHRP triggers the actual GH release burst
This ensures each patient receives a personalized treatment plan based on their medical history, lifestyle, and health goals, minimizing risks and maximizing results
It focuses on lean protein , controlled volume , and digestive ease
N., Breitschaft, A., Knop, F